NCT06138873 Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy
| NCT ID | NCT06138873 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rush University Medical Center |
| Condition | Ventricular Tachycardia |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-10-23 |
| Primary Completion | 2026-11-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-10-23 with a primary completion date of 2026-11-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality have been used. The Ablation Index (AI) is a variable incorporating power delivery in its formula and combining it with CF and time in a weighted equation which aims at allowing for a more precise estimation of lesion depth and quality when ablating VAs. AI guidance has previously been shown to improve outcomes in atrial and ventricular ablation in patients with premature ventricular complexes (PVC). However research on outcomes following AI-guidance for VT ablation specifically in patients with structural disease and prior myocardial infarction remains sparse. The investigators aim at conducting the first randomized controlled trial testing for the superiority of an AI-guided approach regarding procedural duration.
Eligibility Criteria
Inclusion Criteria: * Patient ≥ 18 y.o. * Structural Heart Disease: Ischemic Cardiomyopathy * Sustained Scar-related Monomorphic Ventricular Tachycardia documented by ECG or CIED interrogation Exclusion Criteria: * If clinical ventricular arrhythmia is predominantly PVCs, supraventricular tachycardia, or ventricular fibrillation * Myocardial infarction or cardiac surgery within 6 months * Severe mitral regurgitation * Stroke or TIA within 6 months * Prior VT substrate ablation in the previous 6 months * NYHA functional class IV * Non-ischemic VT substrate
Contact & Investigator
Alexander Mazur, MD
PRINCIPAL INVESTIGATOR
Rush University Medical Center
Frequently Asked Questions
Who can join the NCT06138873 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ventricular Tachycardia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06138873 currently recruiting?
Yes, NCT06138873 is actively recruiting participants. Contact the research team at alexander_mazur@rush.edu for enrollment information.
Where is the NCT06138873 trial being conducted?
This trial is being conducted at Chicago, United States, Boston, United States, Ann Arbor, United States, Rochester, United States and 1 additional location.
Who is sponsoring the NCT06138873 clinical trial?
NCT06138873 is sponsored by Rush University Medical Center. The principal investigator is Alexander Mazur, MD at Rush University Medical Center. The trial plans to enroll 100 participants.